Ebola Virus Disease Treatment

PROJECT SUMMARY Ebola Virus Disease (EVD) has been responsible for over 40 human outbreaks since 1976. The remarkable case fatality ratio, reaching up to 90% in certain outbreaks, has prompted investigations into specific treatments. Despite advancements in EVD care, there is a significant lack of research on adjunctive therapeutics, particularly those targeting the gastrointestinal system. Research during outbreaks highlighted EVD's substantial impact on the gastrointestinal system, including symptoms such as nausea, vomiting, and diarrhea, and the worrisome clinical feature of gastrointestinal hemorrhage. Emerging evidence suggests that EVD may trigger gut bacterial translocation, contributing to secondary bacterial sepsis and high mortality. The impact of gastrointestinal diseases remains unexplored. thousands of individuals were treated during the 2018- 2020 outbreak, providing a valuable dataset for assessing the impact of gastrointestinal therapeutic interventions on EVD mortality. This research aims to address crucial gaps in understanding EVD pathophysiology and improve treatment. Specifically, the project will use the data collected during key outbreaks to evaluate the effects of omeprazole, metronidazole, and albendazole on various EVD outcomes, including mortality, using novel statistical methods including propensity score matching.